FDA launches one-day inspections and expands AI systems Elsa 4.0 and HALO at its headquarters in the United States, introducing a major shift in global pharmaceutical regulation. The move accelerates risk-based oversight and structured-data review, reshaping GMP expectations for manufacturers
